Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 83

Results For "ISA"

1129 News Found

Experts point out key issues for vision loss at ASSOCHAM meet
Healthcare | February 24, 2022

Experts point out key issues for vision loss at ASSOCHAM meet

Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes


Cadila Healthcare is now Zydus Lifesciences
News | February 24, 2022

Cadila Healthcare is now Zydus Lifesciences

Zydus unveils its ‘innovation and care’ centric corporate brand identity


Industry needs to ensure quality standards : S Aparna, Union Pharma Secretary
News | February 24, 2022

Industry needs to ensure quality standards : S Aparna, Union Pharma Secretary

Collaboration in the industry needs to be institutionalised to drive the growth.


Omicron sublineage BA.2 a Variant of Concern: WHO
News | February 23, 2022

Omicron sublineage BA.2 a Variant of Concern: WHO

As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern


Prestige BioPharma’s facility receives EU-GMP certification
Biotech | February 22, 2022

Prestige BioPharma’s facility receives EU-GMP certification

The facility will manufacture its Herceptin biosimilar, Tuznue


UK MHRA approves Marksans  All in One oral solution
Drug Approval | February 22, 2022

UK MHRA approves Marksans All in One oral solution

Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs


Enhertu Phase III results to redefine how metastatic breast cancer is classifed
Biotech | February 21, 2022

Enhertu Phase III results to redefine how metastatic breast cancer is classifed

Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.


Corbevax receives EUA for 12-18 age group
News | February 21, 2022

Corbevax receives EUA for 12-18 age group

It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19


Syncona completes sale of Gyroscope to Novartis
News | February 20, 2022

Syncona completes sale of Gyroscope to Novartis

The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope